Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Cantor Fitzgerald Reiterates Avalo (AVTX) at Overweight, Peak Sales Potential of Pipeline is Underappreciated
March 2, 2022 10:56 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $7.00 price target on Avalo Therapeutics Inc. (NASDAQ: AVTX), following the company's Q4 report.
The analyst quotes: "Post a solid quarter of execution in 4Q21, we are reiterating our Overweight rating and... More
